Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
This study is ongoing, but not recruiting participants.
Study NCT01141491 Information provided by MabVax Therapeutics, Inc.
First Received on June 9, 2010. Last Updated on February 1, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Interventions listed in this trial
Trivalent ganglioside vaccine
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Physiological Effects of Drugs
Sponsors listed in this trial
MabVax Therapeutics, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers